|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:2019
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Descovy
|
|
gptkbp:class
|
NRTI
antiretroviral
|
|
gptkbp:clinical_trial
|
Phase 3
positive outcomes
|
|
gptkbp:clinical_use
|
HIV-1 infection
Pr EP
|
|
gptkbp:combination_drug
|
yes
|
|
gptkbp:contains
|
gptkb:tenofovir_alafenamide
gptkb:emtricitabine
|
|
gptkbp:contraindication
|
hypersensitivity to components
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:drug_interactions
|
minimal
|
|
gptkbp:formulation
|
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Descovy
|
|
gptkbp:indication
|
pre-exposure prophylaxis (Pr EP)
treatment of HIV-1 infection
|
|
gptkbp:ingredients
|
gptkb:emtricitabine
tenofovir alafenamide fumarate
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
high
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_population
|
adults
adolescents
high-risk populations
|
|
gptkbp:pharmacokinetics
|
inhibits reverse transcriptase
once daily dosing
|
|
gptkbp:previous_name
|
no
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
WHO guidelines
CDC guidelines
|
|
gptkbp:requires
|
available
|
|
gptkbp:research
|
ongoing studies
|
|
gptkbp:research_focus
|
HIV prevention strategies
HIV treatment advancements
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
diarrhea
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for effectiveness
|
|
gptkbp:used_for
|
HIV treatment
HIV prevention
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
4
|